Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Major Shareholder Bain Capital Life Sciences Inv Buys 300,000 Shares

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) major shareholder Bain Capital Life Sciences Inv purchased 300,000 shares of Olema Pharmaceuticals stock in a transaction that occurred on Wednesday, January 8th. The shares were purchased at an average cost of $5.76 per share, with a total value of $1,728,000.00. Following the transaction, the insider now directly owns 7,800,000 shares of the company’s stock, valued at $44,928,000. This represents a 4.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Olema Pharmaceuticals Trading Down 4.0 %

NASDAQ:OLMA opened at $4.84 on Tuesday. Olema Pharmaceuticals, Inc. has a 12 month low of $4.60 and a 12 month high of $16.77. The company has a market cap of $277.32 million, a PE ratio of -2.21 and a beta of 2.05. The company has a 50 day simple moving average of $8.20 and a two-hundred day simple moving average of $10.96.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Olema Pharmaceuticals in a research report on Wednesday, December 11th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $27.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Point72 Asset Management L.P. boosted its stake in shares of Olema Pharmaceuticals by 14.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 3,687,374 shares of the company’s stock worth $44,027,000 after acquiring an additional 475,447 shares during the last quarter. State Street Corp boosted its stake in shares of Olema Pharmaceuticals by 1.1% during the 3rd quarter. State Street Corp now owns 1,969,963 shares of the company’s stock worth $23,521,000 after acquiring an additional 21,986 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Olema Pharmaceuticals by 10.8% during the 3rd quarter. Wellington Management Group LLP now owns 1,002,685 shares of the company’s stock worth $11,972,000 after acquiring an additional 97,428 shares during the last quarter. Great Point Partners LLC boosted its stake in shares of Olema Pharmaceuticals by 25.5% during the 3rd quarter. Great Point Partners LLC now owns 1,000,000 shares of the company’s stock worth $11,940,000 after acquiring an additional 203,120 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its stake in shares of Olema Pharmaceuticals by 9.9% during the 3rd quarter. Victory Capital Management Inc. now owns 851,512 shares of the company’s stock worth $10,167,000 after acquiring an additional 76,720 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.